LON:C4XD C4X Discovery (C4XD) Share Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About C4X Discovery Stock (LON:C4XD) Get C4X Discovery alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolume3.77 million shsAverage Volume1.18 million shsMarket Capitalization£30.27 millionP/E Ratio300.00Dividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview C4X Discovery Holdings plc operates as drug discovery company in the United Kingdom. The company provides Taxonomy3, a novel in silico platform technology that utilizes proprietary mathematical algorithms to perform complex multivariate analysis of genetic data; Conformetrix, a technology platform which allows 3D-shapes of free drug molecules to be measured from experimental data, giving medicinal chemists new and unprecedented insights into the behavior and physical properties of drug molecules; and 4Sight for visualizing 4D molecules in virtual reality research scientists to view, understand and interrogate the complex, multidimensional molecular shape data of drug molecules. Its product pipeline includes Orexin-1, a receptor antagonist for the treatment of addictive disorders; NRF-2 activator to treat various inflammatory diseases; IL-17A inhibitor for inflammation diseases; a4ß7 integrin inhibitors for the treatment of inflammatory bowel disease; and MALT-1 inhibitors to treat hematological cancer. The company was formerly known as Schosween 24 plc and changed its name to C4X Discovery Holdings plc October 2014. C4X Discovery Holdings plc was incorporated in 2007 and is based in Manchester, the United Kingdom. Read More Receive C4XD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for C4X Discovery and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. C4XD Stock News HeadlinesC4X Discovery announces selection of a once-daily development candidate from its α4β7 inhibitor programmeSeptember 22, 2025 | uk.finance.yahoo.comPatientSeek identifies a genetic signature that separates a4b7 integrin therapy responder and non-responder populations in inflammatory bowel diseaseSeptember 17, 2024 | markets.businessinsider.comLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.May 17 at 1:00 AM | InvestorPlace (Ad)C4X Discovery Holdings PLC: C4X Discovery Holdings Limited announces progress on immuno-inflammation programmes and appointment of new Board membersJuly 22, 2024 | finanznachrichten.deC4X Discovery Holdings PLC: C4X Discovery announces progress on immuno-inflammation programmes and appointment of new Board membersJuly 22, 2024 | finanznachrichten.deC4X Discovery Holdings Limited announces progress on immuno-inflammation programmes and appointment of new Board membersJuly 22, 2024 | finance.yahoo.comUK biotech, what’s in it for retail investors?July 19, 2024 | ft.comC4X Discovery to Delist From AIM Due to Downturn in Financial MarketsMarch 27, 2024 | marketwatch.comSee More Headlines C4XD Stock Analysis - Frequently Asked Questions How were C4X Discovery's earnings last quarter? C4X Discovery Holdings plc (LON:C4XD) issued its earnings results on Wednesday, April, 29th. The company reported ($5.02) earnings per share (EPS) for the quarter, beating the consensus estimate of ($5.50) by $0.48. C4X Discovery had a trailing twelve-month return on equity of 55.38% and a net margin of 42.81%. How do I buy shares of C4X Discovery? Shares of C4XD stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of C4X Discovery own? Based on aggregate information from My MarketBeat watchlists, some other companies that C4X Discovery investors own include The Berkeley Group (BKG), B&M European Value Retail (BME), Coats Group (COA), 4D pharma (DDDD), genedrive (GDR), Greencore Group (GNC) and Intel (INTC). Company Calendar Last Earnings4/29/2020Today5/17/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolLON:C4XD CIKN/A Webwww.c4xdiscovery.com Phone+44-161-2355085FaxN/AEmployees49Year FoundedN/AProfitability EPS (Trailing Twelve Months)GBX 0.04 Trailing P/E Ratio300.00 Forward P/E RatioN/A P/E GrowthN/ANet Income£10.57 million Net Margins42.81% Pretax MarginN/A Return on Equity55.38% Return on Assets28.04% Debt Debt-to-Equity Ratio1.05 Current Ratio15.31 Quick Ratio9.82 Sales & Book Value Annual Sales£24.68 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow4.00 Book ValueGBX 10 per share Price / BookN/AMiscellaneous Outstanding Shares252,230,000Free FloatN/AMarket Cap£30.27 million OptionableNot Optionable Beta0.23 10 Best Stocks to Own in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Spring 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free Report This page (LON:C4XD) was last updated on 5/17/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredWhy this tiny stock may move before the SpaceX IPO dropsThe projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...Behind the Markets | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredPH: Do THESE 4 things to your bank account now …In a few short months, the US government could gain unprecedented powers over personal bank accounts - includi...Weiss Ratings | SponsoredRead this warning immediatelyPorter Stansberry, founder of one of the world's largest financial research firms, says he's breaking the bigg...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding C4X Discovery Holdings plc Please log in to your account or sign up in order to add this asset to your watchlist. Share C4X Discovery With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.